Retinitis Pigmentosa
Conditions
Keywords
Transcorneal Electrical Stimulation, TES, Retinitis Pigmentosa, RP
Brief summary
Several studies have shown that TES in RP patients may help to slow the progressive deterioration of this degenerative disease. The end point of this clinical trial is to slow or stop disease progression with weekly treatment using TES for 1 year.
Detailed description
The following proposed study (ICM1TES/RP) will investigate the therapeutic aspects of transcorneal electrical stimulation (TES) on the eye in patients with retinitis pigmentosa (RP). It will utilize the Okuvision TES system, a Wills Eye Hospital-sponsored FDA non-significant risk (NSR) medical device, OkuStim® (CE-marked OkuStim®) for the application of electrical stimulation directly to the eye via a corneal contact electrode. Study Design - Multi-center, prospective, randomized sham controlled 1:1 Clinical trial. Study treatments - Patients will be randomized in a 1:1 ratio. Patients in treatment group will have TES at 200% of phosphene threshold for 30 minutes once weekly for 52 weeks in both eyes. Patients in sham group will also wear electrodes on both eyes, but no energy is turned on and both eyes are sham. Duration of study - anticipated duration is 36 months, 12 months for recruitment, 12 months for treatment and sham groups and followed for 18 months, plus 6 months for analysis. Inclusion Criteria - Diagnosis of RP, 22-80 years of age, no other ocular disease, able to complete all visits. Treatments - TES, 30 minute treatment weekly for 52 weeks at 0.8mA Number of patients - 90 patients in treatment arm and 90 patients in sham arm. Electrodes will be placed on both eyes, both eyes will be treated in treatment group and in the sham group both eyes will be considered. However due to the possibility of drop out using 15% we will recruit 210 patients (15 patients per center). Screening - 1. VA & Phosphene threshold evaluation 2. Vfiii4e, vfVe, Octopus 900, complete eye exam, fundus photo, OCT and Contrast sensitivity, electro-physiology. 3. Eligibility requirements met, then schedule baseline. Tests - Base Line: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, fundus photo, OCT, Contrast sensitivity, NEI VFQ-25, Photopic B-wave ERG, blood draw for genetic test (unless genetic profile has been done). 3 Month visit: VA, eye exam, Phosphene threshold, OCT & Photopic B-wave. 6 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, phosphine threshold & Photopic B-wave. 9 Month visit: VA, eye exam, Phosphene threshold, OCT & Photopic B-wave. 12 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, NEI VFQ-25, phosphene threshold & Photopic B-wave 18 Month visit: VA, vfiii4e, vfVe, Octopus 900, complete eye exam, OCT & Contrast sensitivity, NEI VFQ-25 & phosphene threshold & Photopic B-wave.
Interventions
DEVICETranscorneal Electrical Stimulation using Okustim device
The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).
Sponsors
Okuvision GmbH
Wills Eye
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
22 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with Retinitis Pigmentosa. 2. Adult patients, 22-80 years of age, having provided written informed consent and HIPAA authorization. 3. LogMAR VA 1.00 or better in both eyes. 4. Octopus 900 Central Visual Field ≥10 degrees diameter around central fixation using stimulus sizes III4e and V4e in both eyes on kinetic testing. 5. Agree to discontinue Vitamin A use and no intake for at least 2 months prior to baseline visit.
Exclusion criteria
1. Visual field loss as demonstrated by Octopus 900 kinetic perimetry as \<10 deg of remaining central visual field using stimulus sizes III4e and V4e. 2. Due to distance or other reason, patients unable to travel to Philadelphia or respective centers for the treatment procedures and follow-up examinations. 3. Diabetic retinopathy 4. Ocular neovascularisation of any origin 5. After arterial or venous occlusion 6. After retinal detachment or any vitreoretinal surgery with or without implantation. 7. Silicone oil tamponade 8. Dry or exudative age-related macular degeneration 9. Macular edema involving the foveal center as determined by SD-OCT 10. All forms of glaucoma 11. Any form of corneal degeneration that reduces visual acuity 12. Systemic diseases that are difficult to control or manage, which could hinder regular attendance at follow-up examinations 13. Patients in a permanently poor general condition, which could hinder regular attendance at follow-up examinations 14. Patients in whom phosphenes are only inducible at greater than, but not including, 0.8 mA. 15. Forms of mental illness related to the bipolar affective and schizoid-affective disorders, epilepsy, and all forms of dementia 16. Simultaneous participation in another interventional study or history of interventions whose effect may still persist 17. Current pregnancy, or being a woman with childbearing potential who is unwilling to use medically acceptable means of birth control for the study duration, or a woman unwilling to perform a pregnancy test at study entry 18. Any patient can be excluded from the study as determined by the Principal Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Octopus vfiii4e (Progressive slowing of Visual Field deterioration) | 76 weeks | Octopus vfiii4e test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76 to analyze progressive slowing of Visual Field deterioration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity (VA) | 76 weeks | VA testing will be done at all visits |
| Contrast sensitivity | 76 weeks | Contrast sensitivity testing will be done at Baseline visit, Week 26, Week 53 and Week 76 |
| NEI-VFQ-25 total score & subscores | 53 weeks | NEI-VFQ-25 survey will be filled out at Baseline visit and at Week 53 |
| Photopic b-wave ERG | 76 weeks | Photopic b-wave ERG test will be done at Baseline visit, Week 13, Week 26, Week 39, Week 53 and Week 76 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Octopus GATE (static) | 76 weeks | Octopus GATE (static) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint. |
| Octopus vf V4e (kinetic) | 76 weeks | Octopus vf V4e (kinetic) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint. |
| SD-OCT (ez analysis) | 76 weeks | SD-OCT (ez analysis) test will be done at Screening visit, Baseline visit, Week 26, Week 53 and Week 76. This is an exploratory efficacy endpoint. |
| Change in phosphene threshold detection levels | 76 weeks | Change in phosphene threshold detection levels will be done at Screening visit, Baseline visit, Week 13, Week 26, Week 39, Week 53 and Week 76. This is an exploratory efficacy endpoint. |
Countries
United States
Outcome results
None listed